Efficiency and influencing factors of interferon therapy for 1-6 years old children with chronic hepatitis B

潘静,张敏,姚甜甜,程浩,张政,王贵强,王艳

DOI: https://doi.org/10.3760/cma.j.issn.1673-4092.2020.03.009

2020-01-01

International Journal of Virology

Abstract:Objective:To investigate the efficiency and influencing factors of combined therapy with interferon alpha (IFNα) and nucleotide analogues (NA) antiviral drug in the treatment of chronic hepatitis B (CHB) in children.Methods:Clincial data of 95 1-6 years old children diagnosed as CHB by liver biopsy were collected, including IFNα monotherapy group (n=32) and combined therapy of IFNα and lamivudine (LAM) group (n=63). The patients were classified into HbsAg negative group and non-HbSAg negative group according to the therapeutic results at 48 weeks.Results:After 48 weeks and 96 weeks of antiviral treatment, the HbeAg negative rates were 50.5% and 70.5%, respectively while HBsAg negative rates were 34.7% and 50.5%, respectively. Multivariate logistic regression analysis showed that age, gender (male) and baseline HBsAg level were the independant influencing factors for HBsAg negative after 48 weeks of treatment ( P<0.05). HBsAg levels at 12, 24 and 36 weeks had high predictive values for the treatment results at 48 weeks. The AUC values were all higher than 0.8 while all the sensitivities and specificities exceeded 70%. The B lymphocytes count at 36 weeks of treatment showed high value of prediction with AUC of 0.975 and sensitivity and specificity as 69.2% and 85.2%, respectively. Conclusions:IFNα was effective in HBeAg-positive CHB children aged 1-6 years old. Young age, low HBsAg level and female were predictors of HBsAg negative. The detection of peripheral blood lymphocyte subsets in CHB children can be helpful to judge the prognosis.